Press Releases

Emergent BioSolutions to Participate in First Quarter 2017 Investor Conferences

...

Emergent BioSolutions Receives Health Canada Approval for Botulism Antitoxin

...

Emergent BioSolutions to Support HHS Anthrax Preparedness Strategy With Up to $1 Billion in BioThrax Deliveries to the Strategic National Stockpile

...

Dr. Kathryn C. Zoon Appointed to Emergent BioSolutions Board of Directors

...

Emergent BioSolutions Reports Third Quarter and Nine Months 2016 Financial Results

...

Emergent BioSolutions to Release Third Quarter 2016 Financial Results and Conduct a Conference Call on November 7, 2016

...

Emergent BioSolutions Provides Update on Status of BioThrax Procurement Contract and Discussions With CDC

...

Emergent BioSolutions Awarded BARDA Contract for Advanced Development and Delivery of NuThrax, a Next Generation Anthrax Vaccine, Valued at Up to $1.6 Billion

...

Emergent BioSolutions Receives FDA Approval for Large-Scale Manufacturing of BioThrax in Building 55

...

Emergent BioSolutions Announces Conversion Rate Adjustment to 2.875% Convertible Senior Notes Due 2021 Following Spin-Off of Aptevo Therapeutics

...

CDC Exercises Contract Option Valued at $11.6 Million to Further Support Emergent BioSolutions’ Vaccinia Immune Globulin

...

Emergent BioSolutions Reports Second Quarter and Six Months 2016 Financial Results

...